CD38-directed Cytolytic Antibody drugs

5 medications in the FDA established pharmacologic class “CD38-directed Cytolytic Antibody”.

DrugTypeNDC products
Sarclisa
isatuximab
Rx2
Darzalex
Daratumumab
Rx1
Darzalex Faspro
daratumumab and hyaluronidase-fihj (human recombinant)
Rx1
Darzalex IV
Daratumumab
Rx1
Sarclisa Escena
isatuximab-irfc
Rx1